Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 10, 2024
Abstract
Despite
numerous
studies
on
second-line
therapies
in
metastatic
pancreatic
cancer,
there
is
no
randomized
study
evaluating
the
efficacy
of
gemcitabine
plus
nab-paclitaxel
as
a
treatment.
This
aims
to
examine
therapy.
In
this
retrospective
study,
total
218
patients
from
23
centers
were
included
and
median
age
60.2
years.
The
primary
endpoint
was
progression-free
survival
(PFS),
secondary
endpoints
overall
(OS),
treatment
based
ECOG
performance
status
(PS),
tumor
marker
(CEA,
CA
19
−
9)
levels.
with
nab-paclitaxel,
PFS
5.1
months
(95%
CI,
5.6
7.1),
OS
8.6
7.3
10.0).
Median
6.6
normal
CEA
levels
compared
4.4
high
(P
=
0.01).
6
PS
0–1
3.8
2
<
demonstrates
contribution
both
cancer.
We
believe
it
good
option,
especially
for
younger
PS.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(14), P. 7530 - 7530
Published: July 9, 2024
Aging
is
a
multifaceted
process
influenced
by
hereditary
factors,
lifestyle,
and
environmental
elements.
As
time
progresses,
the
human
body
experiences
degenerative
changes
in
major
functions.
The
external
internal
signs
of
aging
manifest
various
ways,
including
skin
dryness,
wrinkles,
musculoskeletal
disorders,
cardiovascular
diseases,
diabetes,
neurodegenerative
cancer.
Additionally,
cancer,
like
aging,
complex
disease
that
arises
from
accumulation
genetic
epigenetic
alterations.
Circadian
clock
dysregulation
has
recently
been
identified
as
an
important
risk
factor
for
cancer
development.
Natural
compounds
herbal
medicines
have
gained
significant
attention
their
potential
preventing
age-related
diseases
inhibiting
progression.
These
demonstrate
antioxidant,
anti-inflammatory,
anti-proliferative,
pro-apoptotic,
anti-metastatic,
anti-angiogenic
effects
well
circadian
regulation.
This
review
explores
cancers,
specific
natural
targeting
key
features
these
conditions.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(4), P. 1129 - 1129
Published: Feb. 10, 2025
Pancreatic
ductal
adenocarcinoma
(PDAC)
is
one
of
the
leading
causes
death
worldwide,
and
its
global
burden
has
increased
significantly
over
past
few
years.
The
incidence
pancreatic
cancer
also
in
United
States,
most
this
increase
attributed
to
population’s
aging
process
addition
rise
prevalence
risk
factors
such
as
obesity,
diabetes,
smoking,
alcohol
intake.
Most
patients
with
present
advanced
unresectable
or
metastatic
disease.
Only
a
at
an
early
stage
localized
disease,
multidisciplinary
approach
required
maximize
survival
outcomes.
surgical
option
for
surgery’s
safety
efficacy
have
been
improved
recent
years
due
increasing
use
minimally
invasive
techniques.
Moreover,
systematic
chemotherapy
used
had
significant
impact
on
survival.
More
recently,
neoadjuvant
therapy
along
radiation
therapy,
optimizing
among
those
patients.
Targeted
therapies
introduced
based
genetic
testing
shown
promising
results.
immune
checkpoint
inhibitors
targeted
agents
PARP
vaccines
emerged
optimal
results
terms
To
conclude,
considered
disease
poor
long-term
survival;
however,
developments
pharmacotherapy
changed
treatment
outcomes
Our
review
summarizes
ongoing
therapeutic
options
local
cancer.
It
new
state-of-the-art
that
are
trials,
which
can
change
perspective.
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(10), P. 2175 - 2175
Published: Sept. 25, 2024
Pancreatic
ductal
adenocarcinoma
(PDAC),
a
leading
cause
of
cancer
mortality
in
the
United
States,
presents
significant
treatment
challenges
due
to
its
late
diagnosis
and
poor
prognosis.
Despite
advances,
five-year
survival
rates
remain
dismally
low,
with
only
fraction
patients
eligible
for
potentially
curative
surgical
interventions.
This
review
aims
comprehensively
examine
current
landscape
targeted
therapies
PDAC,
focusing
on
recent
developments
precision
medicine
approaches.
We
explore
various
molecular
targets,
including
KRAS
mutations,
DNA
damage
repair
deficiencies,
mismatch
pathway
alterations,
rare
genetic
fusions.
The
discusses
emerging
therapies,
such
as
PARP
inhibitors,
immune
checkpoint
novel
agents,
like
RET
NTRK
inhibitors.
analyze
results
key
clinical
trials
highlight
potential
these
approaches
specific
patient
subgroups.
Recent
PDAC
research
have
emphasized
oncology,
facilitated
by
next-generation
sequencing
identification
epigenetic
alterations.
approach
tailors
treatments
individual
profiles,
improving
outcomes
reducing
side
effects.
Significant
strides
been
made
classifying
into
subtypes,
enhancing
therapeutic
precision.
mutations
genes
KRAS,
along
advancements
small
molecule
offers
new
hope.
Furthermore,
targeting
pathways
immunotherapeutic
strategies
also
show
promising
results.
As
evolves,
integrating
conventional
might
improve
quality
life
patients,
underscoring
shift
towards
more
personalized
paradigm.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 11, 2025
Poly-ADP-ribosylation
(PARylation)
is
a
post-translational
modification
in
which
ADP-ribose
added
to
substrate
proteins.
PARylation
mediated
by
superfamily
of
ADP-ribosyl
transferases
known
as
PARPs
and
influences
wide
range
cellular
functions,
including
genome
integrity
maintenance,
the
regulation
proliferation
differentiation.
We
others
have
recently
reported
that
SH3
domain-binding
protein
2
(3BP2)
plays
role
bone
metabolism,
immune
system
regulation,
cytokine
production.
Additionally,
has
gained
attention
target
for
cancer
treatment.
In
this
review,
we
provide
an
overview
PARylation,
its
involvement
several
signaling
pathways
related
immunity,
potential
combination
therapies
with
PARP
inhibitors
checkpoint
inhibitors.
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: April 5, 2025
Despite
numerous
studies
on
second-line
therapies
in
metastatic
pancreatic
cancer,
there
is
no
randomized
study
evaluating
the
efficacy
of
gemcitabine
plus
nab-paclitaxel
as
a
treatment.
This
aims
to
examine
therapy.
In
this
retrospective
study,
total
218
patients
from
23
centers
were
included.
The
primary
endpoint
was
progression-free
survival
(PFS),
secondary
endpoints
included
overall
(OS),
treatment
based
ECOG
performance
status
(PS),
and
tumor
marker
(CEA,
CA
19
-
9)
levels.
with
nab-paclitaxel,
median
PFS
5.1
months
(95%
CI,
5.6
7.1),
OS
8.6
7.3
10.0).
Median
6.6
normal
CEA
levels
compared
4.4
high
(P
=
0.01).
6
PS
0-1
3.8
2
<
demonstrates
contribution
both
cancer.
It
found
be
good
option
especially
for
young
PS.
Journal of Virology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 11, 2025
ABSTRACT
Vesicular
stomatitis
virus
(VSV)
is
a
promising
oncolytic
(OV)
against
different
malignancies,
including
pancreatic
ductal
adenocarcinoma
(PDAC).
In
this
study,
we
examined
the
role
of
methyltransferase-like
3
(METTL3),
catalytic
subunit
cellular
writer
complex
that
responsible
for
N6-methyladenosine
(m6A)
RNA
modification,
as
potential
host
factor
VSV
replication
in
PDAC
cells.
METTL3
was
previously
shown
to
be
upregulated
PDAC,
where
it
promotes
cancer
cell
proliferation,
invasion,
and
chemoresistance.
The
impact
on
life
cycles
viruses
varies
depending
both
type.
Additionally,
plays
positive
non-PDAC
cells
via
m6A
modification
RNAs,
which
attenuates
innate
antiviral
responses.
10
human
lines
uncovered
two
distinct
outcomes.
depletion
did
not
affect
with
defective
signaling,
suggesting
directly
involved
replication.
contrast,
dramatically
inhibited
functional
signaling.
We
show
result
due
RIG-I-dependent
induction
virus-independent,
intrinsic
state
METTL3-depleted
This
marked
by
type-III
(but
type
I
or
II)
interferon
secretion
constitutive
overexpression
sensors
[RIG-I
(DDX58),
MDA5
(IFIH1),
LGP2
(DHX58)],
transactivators
(STAT1,
IRF7,
IRF9),
diverse
subset
effectors,
MX1,
OAS1/2/3,
IFIT1/3.
IMPORTANCE
Pancreatic
deadly
extremely
challenging
disease,
making
essential
develop
new
treatment
options
improve
patient
survival
rates.
One
approach
use
replication-competent
“oncolytic
viruses”
designed
specifically
target
destroy
while
sparing
healthy
ones.
To
create
effective
therapies
cancer,
crucial
identify
factors
influence
successful
infection
these
viruses.
Here,
demonstrate
protein
METTL3,
promote
resistance
chemotherapy,
most
tested
lines.
induces
chronic
inhibits
viral
Our
study
important
understanding
improving
virus-based
therapies.
Translational Cancer Research,
Journal Year:
2024,
Volume and Issue:
13(6), P. 2751 - 2766
Published: June 1, 2024
Pancreatic
ductal
adenocarcinoma
(PDAC),
which
accounts
for
the
vast
majority
of
pancreatic
cancer
(PC),
is
a
highly
aggressive
malignancy
with
dismal
prognosis.
Age
shown
to
be
an
independent
factor
affecting
survival
outcomes
in
patients
PDAC.
Our
study
aimed
identify
prognostic
factors
and
construct
nomogram
predict
PDAC
aged
≥60
years.
